News about "Sandoz"

Strides Pharma Acquires Sandoz's Generic Brands to Expand African Business

Strides Pharma has acquired multiple generic brands from Sandoz to expand its African business, a move expected to position it among the top five pharma companies in Sub-Saharan Africa and more than double its regional presence.

Sandoz | 19/03/2026 | By News Bureau

Samsung Bioepis Partners with Sandoz for Next-Gen Biosimilar Candidates

Samsung Bioepis has partnered with Sandoz to develop and commercialise up to five biosimilar candidates, including SB36 (vedolizumab), across global markets, excluding select Asian regions, strengthening its pipeline in immunology and oncology.

Sandoz | 19/03/2026 | By News Bureau

Lupin Secures European Commission Approval for Ranluspec, Biosimilar Ranibizumab

European Commission clears Lupin’s biosimilar ranibizumab, Ranluspec, for multiple retinal disorders; Sandoz to commercialise across the EU, expanding access to affordable biologics.

Sandoz | 24/02/2026 | By News Bureau |  125

Alembic Pharma Wins USFDA Approval for Travoprost Ophthalmic Solution

Alembic Pharmaceuticals has secured USFDA approval for its Travoprost Ophthalmic Solution, with the ANDA deemed therapeutically equivalent to the reference listed drug Travatan Z (0.004%) from Sandoz.

Sandoz | 18/12/2025 | By News Bureau |  122

Sandoz and EirGenix Ink Global Licensing Deal for Pertuzumab Biosimilar

Sandoz, the global leader in affordable medicines, has signed a global license agreement with Taiwanese biotech company EirGenix to commercialise a proposed biosimilar of the oncology medicine pertuzumab. The milestone-based deal, valued at up to USD 152 million, includes an upfront payment and potential market-based incentives.

Sandoz | 13/11/2025 | By Dineshwori |  410

Sandoz Partners with Elawan Energy to Decarbonize European Operations

Sandoz has signed a 10-year virtual Power Purchase Agreement (PPA) with Elawan Energy to co-develop 150 MW of new solar projects in Valladolid, Castilla y Leon, Spain.

Sandoz | 12/08/2025 | By Dineshwori |  232

Sandoz Reports Strong H1 2025 Results, Accelerated Growth in Biosimilars and Generics

Sandoz has reported strong financial results for the first half of the financial year 2025, with the company’s net sales reaching USD 5.2 billion. Growth accelerated in the second quarter, driven by solid performance across both the generics and biosimilars businesses.

Sandoz | 07/08/2025 | By Dineshwori |  729

Sandoz Reports Strong H1 2025 Results, Accelerated Growth in Biosimilars and Generics

Sandoz has reported strong financial results for the first half of the financial year 2025, with the company’s net sales reaching USD 5.2 billion. Growth accelerated in the second quarter, driven by solid performance across both the generics and biosimilars businesses.

Sandoz | 07/08/2025 | By Dineshwori |  729

Sandoz to Acquire Just-Evotec Biologics in USD 300 Million Deal

Sandoz has signed a non-binding term sheet with Evotec SE, paving the way for the potential acquisition of Just–Evotec Biologics EU SAS for approximately USD 300 million.

Sandoz | 30/07/2025 | By Dineshwori |  364

FDA Drug Approvals Fall in 2024, But Small Pharma Fuels Innovation Surge

The US Food and Drug Administration (FDA) approved 127 innovator and biosimilar drugs in 2024, marking a decline from the 149 approvals recorded in 2023, according to a report by leading data and analytics firm GlobalData.

Sandoz | 19/07/2025 | By Dineshwori |  484